Fair point, Beach. Even if they don't have a dominant position based on other upcoming trials, with obviously an immense amount of a risk since they are less mature, any green light from the FDA would open the doors for off label applications and further legitimize 302 as a force multiplier in many indications. I'm not expecting a premature NDA based on the interim results, but this is most definitely not a show stopper for 302.
Assuming you're still frequenting this board, what are your current thoughts on THLD's long term potential? You were quite bullish historically, but haven't heard much from you over the past few months. . .
Interesting. . . CYTR easily surpassed 302's results for at least PFS in their P2 trial - "In an intent-to-treat analysis, the investigator-assessed median PFS was 8.4 months for aldoxorubicin patients versus 4.7 months for doxorubicin patients (p=0.0002), while the blinded central lab review indicated that median PFS for aldoxorubicin patients was 5.7 months versus 2.8 months for doxorubicin patients (p=0.018). "